Kamada to Commercialize Three Biosimilar Products in Israel
Shots:
- Kamada signs an agreement with two undisclosed international pharmacies to commercialize three biosimilar product candidates in Israel. The two pharmaceutical companies will be responsible for the development- manufacturing- and supply of three products
- Following the approval from EMA and IMOH- the three products are expected to be launched in Israel b/w 2022 and 2024
- The collaboration will expand Kamada’s biosimilar portfolio in Israel which already includes six products previously licensed from Alvotech
Ref: GlobeNewswire | Image: Globes English
Click here to read the full press release
Tags
Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com
